Jazz Pharmaceuticals Gets European Commission OK for Enrylaze
September 21 2023 - 5:20PM
Dow Jones News
By Ben Glickman
Jazz Pharmaceuticals on Thursday said it had received market
authorization from the European Commission for its treatment for
certain types of leukemia and lymphoma.
The Dublin-based pharmaceutical company said that Enrylaze could
now be used as a component of a multi-agent chemotherapeutic
regiment in the treatment of acute lymphoblastic leukemia and
lymphoblastic lymphoma.
Enrylaze is currently approved under the name Rylaze in the U.S.
and Canada.
The approval from the European Commission was based on Phase 2/3
trial data.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 21, 2023 18:05 ET (22:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Apr 2024 to May 2024
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From May 2023 to May 2024